VX18-659-106: A Phase 3, Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Project: Research project

Project Details

StatusActive
Effective start/end date10/18/1810/17/50

Funding

  • Vertex Pharmaceuticals Incorporated